Press Releases

Accuray and Christie InnoMed Sign Exclusive Sales Agent Agreements for Radiation Therapy Systems in Canada SUNNYVALE, Calif., March 5, 2015 -- Accuray Incorporated (Nasdaq: ARAY) and Christie InnoMed Inc. announced today that they have entered into sales agent agreements involving the CyberKnife® and TomoTherapy® System product portfolios in Canada. Under the terms of these agreements, Christie InnoMed will be the exclusive sales agent for Accuray products in this region. Read More »
Erste Patientenbehandlung mit dem CyberKnife® M6™-System und dem InCise™ Multileaf-Kollimator ist abgeschlossen SUNNYVALE, Kalifornien, 2. März 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) meldete heute die erste unter Einsatz des CyberKnife® M6™-Systems mit dem InCise™ Multileaf-Kollimator (MLC) abgeschlossene Patientenbehandlung. Die Behandlung wurde multidisziplinär durch Dr. Steven Burton von der Abteilung für Radioonkologie und Dr. Johnathan Engh von der Abteilung für Neurochirurgie am UPMC in Pittsburgh (Pennsylvania) durchgeführt. Das UPMC war in Kooperation mit Accuracy eines der Evaluierungszentren für InCise MLC. Read More »
Le premier traitement d'un patient avec le système CyberKnife® M6™ et le collimateur multilames InCise™ a été mené à terme

SUNNYVALE, Californie, 2 mars 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq : ARAY) a annoncé aujourd'hui que le premier traitement d'un patient a été mené à terme à l'aide du système CyberKnife® M6™ couplé au collimateur multilames (MLC) InCise™. L'administration du traitement reflète les efforts multidisciplinaires du Dr Steven Burton du département de radio-oncologie et du Dr Johnathan Engh du département de neurochirurgie de l'UPMC de Pittsburgh, Pennsylvanie.

Read More »
First Patient Treatment with the CyberKnife® M6™ System and the InCise™ Multileaf Collimator Has Been Completed SUNNYVALE, Calif., March 2, 2015 -- Accuray Incorporated (Nasdaq: ARAY) announced today that the first patient treatment has been completed using the CyberKnife® M6™ System with the InCise™ Multileaf Collimator (MLC). The treatment was administered as a multidisciplinary effort between Dr. Steven Burton from the Department of Radiation Oncology and Dr. Johnathan Engh from the Department of Neurosurgery at UPMC in Pittsburgh, Pennsylvania. UPMC was one of the InCise MLC evaluation sites working in collaboration with Accuray. Read More »
Lancaster General Health Receives First Commercial InCise™ Multileaf Collimator for the CyberKnife® M6™ System

SUNNYVALE, Calif., and LANCASTER, PA, February 24, 2015 -- Accuray Incorporated (Nasdaq: ARAY) and Lancaster General Health announced today that the first commercially available InCise™ Multileaf Collimator (MLC) for the CyberKnife® M6™ System has been received by Lancaster. The hospital selected the InCise MLC based on its ability to increase the system’s treatment efficiency and extend its unique capabilities to a broader range of patient cases.

Read More »
Class A User Licenses for Accuray Products Awarded to 16 Hospitals in China SUNNYVALE, Calif., February 17, 2015 -- Accuray Incorporated (Nasdaq: ARAY) announced that class A user licenses for Accuray products were awarded to 16 hospitals during February by the Chinese National Health and Family Planning Commission (NHFPC). TomoTherapy® System licenses were received by 12 hospitals and CyberKnife® System licenses were received by four hospitals Read More »
Accuray to Participate in the Cowen 35th Annual Healthcare Conference SUNNYVALE, Calif., Feb. 9, 2015 (GLOBE NEWSWIRE) -- Accuray Incorporated (Nasdaq: ARAY), announced today that its management is scheduled to present at the Cowen 35th Annual Healthcare Conference in Boston on Monday, March 2, 2015 at 2:10pm ET. A live webcast of the presentation will be available on the Investor Relations page of the Company's website at The webcast replay of the presentation will begin approximately one hour after the conclusion of the live presentation and will be available for approximately 30 days. Read More »
First TomoTherapy® System in Latin America Dedicated Solely to Breast Cancer Care Now Treating Patients SUNNYVALE, Calif., February 4, 2015 – Accuray Incorporated (Nasdaq: ARAY) announced today that the first TomoTherapy® System in Latin America dedicated solely to the treatment of breast cancer is now operational at FUCAM (Fundacion de Cancer de Mama) in Mexico City. More than 120 women have been treated with the innovative radiation therapy technology since the center began using it over two months ago. FUCAM’s decision to install the TomoTherapy System reinforces growing medical community support for its use as a mainstream treatment to improve tumor control with reduced toxicities. Read More »